

This is a repository copy of *IL-6 and hsCRP in Somatic Symptom Disorders and related disorders*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/168433/>

Version: Published Version

---

**Article:**

Van Der Feltz-Cornelis, Christina Maria [orcid.org/0000-0001-6925-8956](https://orcid.org/0000-0001-6925-8956), Bakker, Marjan, Kaul, Arvind et al. (3 more authors) (2020) IL-6 and hsCRP in Somatic Symptom Disorders and related disorders. *Brain, Behavior, & Immunity - Health*. 100176. ISSN 2666-3546

<https://doi.org/10.1016/j.bbih.2020.100176>


---

**Reuse**

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



## Full Length Article

## IL-6 and hsCRP in Somatic Symptom Disorders and related disorders

Christina M. van der Feltz-Cornelis<sup>a,\*</sup>, Marjan Bakker<sup>b</sup>, Arvind Kaul<sup>c</sup>, Taco W. Kuijpers<sup>d</sup>, Roland von Känel<sup>e</sup>, Jonna F. van Eck van der Sluijs<sup>f,g</sup>

<sup>a</sup> Department of Health Sciences, Hull York Medical School, University of York, York, UK

<sup>b</sup> Department of Methodology and Statistics, Tilburg University, Tilburg, the Netherlands

<sup>c</sup> St. George's University Hospitals NHS Foundation Trust, London, UK

<sup>d</sup> Emma Children's Hospital, Dept. of Pediatric Immunology, Rheumatology and Infectious Diseases, Amsterdam University Medical Center (Amsterdam UMC), Amsterdam, the Netherlands

<sup>e</sup> Department of Consultation-Liaison Psychiatry and Psychosomatic Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland

<sup>f</sup> Clinical Centre of Excellence for Body, Mind and Health, GGZ Breburg, Tilburg, the Netherlands

<sup>g</sup> Altrecht Psychosomatic Medicine, Zeist, the Netherlands

## ARTICLE INFO

## Keywords:

Somatic Symptom Disorder and related disorders (SSRD)  
interleukin-6 (IL-6)  
high-sensitive C-reactive protein (hsCRP)  
biomarkers  
systemic low grade inflammation (SLI)  
childhood sexual abuse

## ABSTRACT

**Background:** Interleukin 6 (IL-6) and high-sensitivity C-reactive protein (hsCRP) are biomarkers of systemic low-grade inflammation (SLI) in depression and anxiety. The question if SLI in those conditions is related to comorbid chronic medical conditions has not been resolved. DSM-5 Somatic symptom disorders and related disorders (SSRD) are conditions with serious distress related to physical symptoms as main criterion. They can occur in patients with medically unexplained symptoms (MUS) and in patients with known comorbid chronic medical conditions. Often, comorbid depression and anxiety are present. SSRDs offer the opportunity to explore the role of SLI in relation to mental distress, including trauma, MUS, chronic medical conditions and comorbid mental disorder. **AIM:** We hypothesized that increased IL-6 and hsCRP may be directly linked to SLI in SSRD, and that comorbid chronic medical conditions, childhood trauma, current stress and comorbid depression and anxiety may be risk factors that account for some of the variance of SLI in SSRD. **METHODS:** We explored these relationships in a large sample of 241 consecutive outpatients with SSRD. **RESULTS:** Mean hsCRP level was 3.66 mg/l, and mean IL-6 level was 3.58 pg/ml. IL-6 and hsCRP levels were associated with each other:  $\tau = 0.249$ ,  $p < .001$ ; a medium size correlation. Comorbid chronic medical conditions, adverse childhood events other than sexual trauma, and current stress levels were not associated with IL-6 or hsCRP levels. **CONCLUSION:** IL-6 and hsCRP are elevated in SSRD, indicating SLI in SSRD independently of comorbid chronic medical conditions. In clinical research, elevated IL-6 and hsCRP can be used as biomarkers of SLI and can indicate risk for childhood sexual abuse in SSRD. Elevated hsCRP may be a biomarker indicating risk for comorbid depression or high pain levels in SSRD as well.

## 1. Introduction

Research concerning Systemic Low-grade Inflammation (SLI) in mental disorders is gaining ground (Miller et al., 2003; Rief et al., 2010). Prolonged SLI activity, resulting in sickness behaviour (fatigue, pain, mood and cognitive symptoms), may provoke mental disorders (Viljoen, Pantzer, 2005) such as depression (Dantzer et al., 2008; Del Grande da Silva et al., 2016; Simon et al., 2008), Post Traumatic Stress Disorders (PTSD) (Lindqvist et al., 2017) and anxiety disorders (Del Grande da Silva et al., 2016; Kovacs et al., 2016; Vogelzangs et al., 2016). Associations with cytokines such as interleukin-6 (IL-6) have been explored mostly in depressive disorder (Dowlati et al., 2010; Simon et al., 2008) with inconsistent

results (Einvik et al., 2012) which might be explained by possible confounding by comorbid chronic medical conditions such as cardiovascular disorders (Howren et al., 2009). IL-6 plays a role in both innate and adaptive immunity (Scheller et al., 2011). Within the adaptive immune response, IL-6 plays a crucial role in activating antibody-producing B cells to proliferate, leading to an enhanced antibody response. Concentrations of IL-6 are elevated in patients with acute and severe infection (Tsalik et al., 2012) but also in chronic inflammatory disorders such as rheumatoid arthritis and inflammatory bowel disease (Gabay, 2006). Normal concentrations of IL-6 range between 2 and 10 pg/ml. Although IL-6 levels in the normal range do not exclude the possibility of an ongoing inflammatory process such as SLI, it is unclear what might be an indicative IL-6 level for

\* Corresponding author. Department of Health Sciences, MHARG, HYMS, YBRI, University of York, ARRC Building, T204, Heslington, York, YO10 5DN, UK.  
E-mail address: [Christina.vanderfeltz-cornelis@york.ac.uk](mailto:Christina.vanderfeltz-cornelis@york.ac.uk) (C.M. van der Feltz-Cornelis).

SLI in mental disorders.

As part of the innate immune system, IL-6 acts on hepatocytes to induce expression of C-reactive protein (CRP), in what is known as the acute phase response. Depending on lab procedures, normal values for CRP range between 2 and 10 mg/l, and a level of 10 mg or higher is an indicator of a serious infection, trauma or inflammatory condition. (Mayo Clinic, 2020) However, despite a level of <10 being in the normal range, epidemiological and intervention studies found a level of 3–10 mg/l on minor CRP elevation, defined as high-sensitivity CRP (hsCRP), to be prospectively associated with an increased cardiovascular risk (Pfützner, Forst, 2006). A level of 3.0 mg/l or higher is considered to indicate at least in part an inflammatory process, or SLI (Ridker, 2016).

Adverse childhood experiences (ACE) occur in mental disorders such as depressive and anxiety disorders (Van der Feltz-Cornelis et al., 2019). Cytokine levels in depressive disorder may differ between depressed patients who experienced ACE and patients who did not; (Pedrotti Moreira et al., 2018); however, the literature is ambiguous (Grosse, 2016) (Pasco et al., 2010; Powers et al., 2019) as another study found that an association between ACE and hsCRP in depressed individuals disappeared after controlling for socioeconomic factors and health behaviours (Gouin et al., 2017). A meta-analysis revealed an association between CRP but not IL-6 with childhood trauma with larger effect sizes for clinical samples with chronic medical conditions such as cancer compared to general population samples (Baumeister et al., 2016). Based upon the literature, whether current or childhood traumatization is associated with IL-6 and hsCRP and what role chronic medical conditions might play in this link, remains unclear. A group of mental disorders that may be of particular interest for exploring the questions above are Somatic Symptom and Related Disorders (SSRD). They are characterized by physical symptoms that are associated with significant distress and impairment (American Psychiatric Association, 2013). SSRD are a group of conditions that include Somatic Symptom Disorders (SSD), SSD with pain, conversion disorder/functional neurological disorder (CD/FND), and health anxiety and can occur in patients with known chronic medical conditions as well as in patients with medically unexplained symptoms (MUS).

We hypothesize that increased IL-6 and hsCRP may indicate SLI in SSRD, and that comorbid chronic medical conditions, trauma and stress, and comorbid depression and anxiety may be risk factors that account for some of the variance in SLI in SSRD.

Our objectives are to:

1. Describe IL-6 and hsCRP levels and clinical characteristics in patients with SSRD in relation to comorbid chronic medical conditions; ACE, AAE, childhood and adult sexual abuse; current stressful life events (LCU); and comorbid mental disorders
2. Explore if IL-6 and hsCRP levels are associated with each other. Explore which one is better to use as biomarker for SLI in SSRD in clinical research. Explore if there is scope to establish cut-off scores for use as a biomarker for SLI in SSRD in clinical research.

## 2. Methods

This is a cross-sectional observational study. The study sample contains patients with comorbid medical conditions, and patients without comorbid medical conditions. Also, it contains patients with trauma and stress, and patients without, as well as patients with and without comorbid depression and anxiety. This diversity in the sample enables us to evaluate our hypothesis. The Scientific Institutional Review Board of GGZ Breburg approved the study protocol.

Consecutive outpatients diagnosed with SSRD at the Clinical Centre of Excellence for SSRD (CLGG), Tilburg, the Netherlands, from September 2016 until September 2018 were eligible after diagnosis at intake. Patients were excluded if they were <18 years old, did not complete any questionnaires during intake, had IQ < 80 or had substance dependency.

The standard intake procedure has been described elsewhere (Van Eck van der Sluijs et al., 2017) and is summarized below. Medical examination by a physician involved assessment of somatic symptoms by medical history taking; a questionnaire measuring somatic symptoms; physical examination; neurological examination; laboratory assessments; venipuncture according to a biochemical, haematological and immunological lab protocol, including the measurement of hsCRP and IL-6 (ELISA). Immunological lab was taken if physical examination did not suggest an active transient infection. Standardised lab procedures for hsCRP and for IL-6, authorised by the Expert Committee on Biological Standardization (ECBS) of the World Health Organization (WHO), are available (Gaines Das, Poole, 1993; Whicher, 1998). In this study, plasma levels of IL-6 were measured by high sensitivity enzyme linked immunosorbent assay (ELISA; Quantikine HS ELISA R&D systems HS600B) performed by DS2, Dynex Elisa robot automated analyzers. Intra assay precision CV% was in the interval 6.9–7.8; interassay precision CV% was in the interval 6.5–9.6. The detection range of this assay was 0.02–10 pg/ml. None of the respondents had IL-6 levels below the detection limit of 0.02 pg/ml and 4 had values above the reference value of 10 pg/ml, as delineated in the outlier analysis. For hsCRP, immunoturbidimetry by automated analyzers was performed. The declared detection limit was 0.20 mg/l. Specimens were drawn from participants and frozen at –80 C until thawed for assay.

Psychiatric evaluation including exploration of sexual trauma was performed by semi-structured interview to provide SSRD DSM-5 classification and other comorbid DSM-5 classifications (American Psychiatric Association, 2013). Psycho-diagnostic questionnaire assessment of psychological symptoms, ACE, AAE, and stressful life events were performed by questionnaires and Mini-International Neuropsychiatric Interview (MINI) (Sheehan et al., 1998). Patient files and the data-warehouse were assessed for the variables described in Table 1.

Supervision and checks by two supervisors (JvE and CFC) secured the standardization of the intake procedure, the reporting in the electronic patient files, and the data extraction and data-entry by trained assistants.

### 2.1. Statistical analysis

Variables explored were IL-6 and hsCRP, SSRD categories, pain, somatic symptoms and functioning. Elevated hsCRP was defined by a level of 3 mg/L or higher. Elevated IL-6 was established as described in the methods. Covariates were ACE, childhood sexual abuse, current daily life stress measured as Holmes and Rahe life events score (LCU), current trauma measured by AAE, as well as comorbid chronic medical conditions, comorbid mental disorders, age, gender, and marital status.

Regarding the description of clinical characteristics, for the continuous variables, means, SD, medians and range were calculated. For the categorical variables, frequencies and percentages were calculated. This was done for all participants together and for each SSRD category separately. Whether IL-6, hsCRP and clinical characteristics differed between SSRD categories (Table 2) and between patients with and without comorbid chronic medical conditions (Table 3) was explored with a robust one-way ANOVA (SSRD categories) or the non-parametric Wilcoxon-Mann-Whitney test (comorbid chronic medical conditions) if the variable was continuous, and with a chi-square test if the variable was categorical, and p-values reported. To test whether IL-6 and hsCRP levels were associated with any of the clinical characteristics, Kendall's correlation test was performed. Kendall's  $\tau$  is a non-parametric correlation and was chosen because of the skewed distribution of IL-6 and hsCRP in the sample. For categorical characteristics, such as gender and comorbidity, Kendall's  $\tau$  is similar to Wilcoxon-Mann-Whitney test, a non-parametric variant of the independent t-test (Table 4). We used non-parametric tests to take into account the skewed distribution of IL-6 and hsCRP values and the presence of outliers. We performed a sensitivity analysis to deal with outliers for IL-6 and hsCRP values as follows. First, we performed log transformation of IL-6 and hsCRP and all IL-6 and hsCRP values of > 3SD above the mean were taken out of the sample. Then, the

**Table 1**  
Data sources/measurement.

| Factors                              | Classification  | Based on  |
|--------------------------------------|---|---|
| Diagnostic classification            |   |   |
| Type of SSRD                         | Type  | Patient file: intake letter and DSM classification ( <a href="#">American Psychiatric Association, 2013</a> )   |
| Psychiatric comorbidity              | Yes/No  | Patient file: DSM classification (if unclear, also MINI) ( <a href="#">Sheehan et al., 1998</a> )   |
| Personality disorder                 | Yes/No  | Patient file: DSM classification and SCID-2 ( <a href="#">Spitzer et al., 1990</a> )  |
| Anxiety disorder                     | Yes/No  | Patient file: DSM classification (if unclear, also MINI)  |
| Depressive disorder                  | Yes/No  | Patient file: DSM classification (if unclear, also MINI)  |
| Developmental disorder               | Yes/No  | Patient file: DSM classification (if unclear, also MINI)  |
| Comorbid CMC                         | Yes/No  | Patient file: DSM classification, intake report (if needed also ICD classification) ( <a href="#">WHO, 2016</a> )   |
| Psychosocial factors                 |   |   |
| Relationship status                  | Single/Living together or Married/Living apart together/Other   | Patient file: intake or registration form Or Psychodiagnostic examination: INTERMED ( <a href="#">Huysse et al., 1999</a> )   |
| Family composition                   | Single without children/Single with children/With a partner without children/With a partner with children                     | Patient file: intake or registration form Or Psychodiagnostic examination: INTERMED   |
| Social safety net                    | Good (both contact with friends and family)/Moderate (only a single family member or a single friend)/Bad (no friends/family) | Patient file: intake or registration form Or Psychodiagnostic examination: INTERMED   |
| Education level                      | Very low (prim. school)/Low (junior high school)/Medium (High school 2,3,4)/High (bachelor)/Very high (MSc, PG)               | Patient file: intake or registration form Or Psychodiagnostic examination: INTERMED   |
| Work                                 | Employed/Sickness Law/Unemployment benefits/Social benefits/Disability benefits/Retired                                       | Patient file: intake or registration form Or Psychodiagnostic examination: INTERMED   |
| Trauma                               |   |   |
| Early childhood trauma               | Yes<br>No<br>Score  | Patient file: ACE ( <a href="#">Anda et al., 1998</a> ), intake and Psychiatric evaluation. The ACE International Questionnaire (ACE-IQ) is developed by the WHO. Development has been ongoing and for this study, the available version in 2015 was used. This covers mostly ACE indicating family dysfunction, physical, sexual and emotional abuse and neglect by parents or caregivers. It was translated from English to Dutch and back-translated to provide the official Dutch version. ( <a href="#">van der Feltz-Cornelis et al., 2019a</a> ) |
| Recent trauma and recent life stress | Yes/No<br>Score   | Patient file: AAE, LCU ( <a href="#">Holmes and Rahe, 1967</a> ), intake and Psychiatric evaluation   |
| Childhood sexual abuse               | Yes/No  | Patient file: ACE, intake and Psychiatric evaluation  |
| Adult sexual abuse                   | Yes/No  |   |

**Table 1 (continued)**

| Factors            | Classification | Based on  |
|--------------------|----------------|---|
|                    |                | Patient file: AAE, intake and Psychiatric evaluation  |
| Symptoms at intake |                |   |
| Scores:            |                | Physical symptoms were measured using the PSQ51 ( <a href="#">Van Hemert, 2003</a> ), which is a 51-item questionnaire. The total score on the PSQ ranges from 0 to 51 and represents the number of physical symptoms that were regularly or often present in the last week. Higher scores indicated a higher symptom burden. De Waal provided normative data. ( <a href="#">De Waal et al., 2004</a> ) They were also measured by the PHQ15. ( <a href="#">Kroenke et al., 2002</a> ) Higher scores indicated a higher symptom burden. Depression was assessed using the PHQ-9. The PHQ-9 is a reliable 9-item self-report questionnaire, with higher scores indicating higher levels of depressive symptoms ( <a href="#">Kroenke et al., 2009</a> ). Item scores ranged from 0 (not at all) to 3 (nearly every day), and total scores ranged from 0 to 27. Cut-off points of 5, 10, 15, and 20 represent mild, moderate, moderately severe and severe levels of depression. ( <a href="#">Kroenke et al., 2010</a> ) Anxiety was assessed using the GAD-7. The GAD-7 is a reliable 7-item self-report questionnaire that measures symptoms of anxiety during the last 2 weeks. Higher scores indicated a higher symptom burden. GAD-7 scores range from 0 to 21, and cut-off scores of 5, 10, and 15 represent mild, moderate and severe levels of anxiety. ( <a href="#">Spitzer et al., 2006</a> ) |
| PSQ51 =            |                | We used the SF-36 general health domain score to assess general functioning. Studies confirmed the SF-36's validity and reliability. ( <a href="#">Ware and Sherbourne, 1992</a> ) The SF-36 is a self-report questionnaire that contains 36 items, which are distributed across eight scales. Scores range from 0 to 100, where higher scores indicate better general functioning. It was validated in the US and in the Netherlands. ( <a href="#">Ware et al., 1994</a> ; <a href="#">Aaronson et al., 1998</a> ) It is responsive to change. ( <a href="#">McHorney et al., 1993</a> ) Normative data are available. ( <a href="#">Garrat et al., 1994</a> )  |
| PHQ15 =            |                | Chronic non-malignant pain was measured by the Brief Pain Inventory (BPI). ( <a href="#">Tan et al., 2004</a> ) Higher scores indicated a higher symptom burden.  |
| PHQ9 =             |                |   |
| GAD7 =             |                |   |
| SF36 =             |                |   |
| BPI =              |                |   |
| Lab at intake      |                |   |
| Venepuncture       |                | Biochemical, Haematological and immunological lab protocol including hsCRP (immunoturbidimetry) and ELISA for IL-6  |

associations between IL-6 and hsCRP and the characteristics in [Tables 2 and 3](#) were recalculated. If any differences were found in the statistical conclusions, this was reported in the Tables. A regression coefficient for age and IL-6 was obtained by a robust regression analysis to take violations of the normality assumption into account. A chi-square test was used to explore sexual revictimization in patients reporting childhood sexual abuse. We explored if IL-6 and hsCRP levels (continuous) were associated using a Kendalls  $\tau$  correlation. A sensitivity analysis was performed by excluding the outliers.

In order to establish cut-off scores for use in clinical research as a biomarker for SLI in SSRD, several steps were undertaken. As first step, a score of 3.0 mg/l or higher was used as a cut-off score for elevated hsCRP, assuming that a hsCRP score of 3.0 mg/l or higher is an indicator of inflammation ([Ridker, 2016](#)). We then checked which IL-6 value corresponded with the percentage of patients having 3.0 mg/l or higher for hsCRP in our sample, a method used elsewhere ([Cho et al., 2013](#)). As a second step, we took out all outlying values of IL-6 and performed a regression analysis with hsCRP as the predictor and IL-6 levels as the dependent variable to explore which IL-6 value corresponds to a hsCRP level of 3.0 mg/l. We then explored if elevated levels of hsCRP and of IL-6, as established by the method described above, were associated with particular clinical characteristics for which they could be used as biomarker, by comparing patient with and without elevated IL-6 levels ([Table 5](#)) and patient with and without elevated hsCRP levels ([Table 6](#)). Means, median, SD and range are given for the continuous variables and frequencies and percentages for the categorical variables. The non-parametric Wilcoxon-Mann-Whitney test was used to test whether patients with and without elevated levels differed significantly on these variables if the variable was continuous, and with a chi-square test if the

**Table 2**

Clinical and demographic characteristics and p-values for the whole sample and SSRD categories. Percentages are based upon the N per variable.

| IL-6<br>M (SD)<br>Median<br>[Range]                                 | IL-6 without<br>outliers<br>M(SD)<br>Median<br>[Range] | hsCRP<br>M (SD)<br>Median<br>[Range] | Age<br>M (SD) | Gender<br>Male<br>N (%) | LCU<br>M (SD) | AAE<br>M (SD)<br>N (%)<br>N = 233 | ACE<br>M (SD)<br>N (%)<br>N = 233 | Childhood<br>sexual abuse<br>N (%) | Adult<br>sexual<br>abuse | PHQ9<br>M (SD) | GAD7<br>M (SD) | BPI<br>M (SD) | PSQ51<br>M (SD) | PHQ15<br>M (SD) | SF36<br>M (SD) | Somatic<br>comorbidity<br>N (%) |
|---|--|--------------------------------------|---------------|-------------------------|---------------|-----------------------------------|-----------------------------------|------------------------------------|--------------------------|----------------|----------------|---------------|-----------------|-----------------|----------------|---------------------------------|
| SSRD Classification N (%)   |  |                                      |               |                         |               |                                   |                                   |                                    |                          |                |                |               |                 |                 |                |                                 |
| SSRD Total group 241 (100)  |  |                                      |               |                         |               |                                   |                                   |                                    |                          |                |                |               |                 |                 |                |                                 |
| <b>3.58 (16.03)</b>   | 2.12 (1.4)   | 3.66 (4.54)                          | 42.31         | 97                      | 92.38         | <b>1.46</b>                       | 1.75 (2.09)                       | <b>53 (22.2%)</b>                  | 16 (8.2%)                | 14.29          | 11.6           | <b>5.65</b>   | 16.35           | 15.52           | 18.82          | 142 (58.9%)                     |
| <b>1.65</b>   | 1.65   | 2.17                                 | (13.43)       | (40.2%)                 | (93.19)       | <b>(1.72)</b>                     | 144                               |                                    |                          | (6.13)         | (5.39)         | <b>(2.5)</b>  | (8.93)          | (5.57)          | (3.32)         |                                 |
| <b>[0.62–226]</b>   | <b>[0.62–9.65]</b>                                     | <b>[0.2–31.14]</b>                   |               |                         |               | <b>140</b>                        | (61.8%)                           |                                    |                          |                |                |               |                 |                 |                |                                 |
| <b>Somatic Symptom Disorder (SSD) 176(73%)</b>                      |  |                                      |               |                         |               |                                   |                                   |                                    |                          |                |                |               |                 |                 |                |                                 |
| <b>2.16 (1.82)</b>  | 2.06 (1.4)   | 3.61 (4.57)                          | 42.36         | 74                      | 95.6          | 1.49                              | 1.65 (1.97)                       | 33 (18.9%)                         | 10 (7.2%)                | 14.36          | 11.62          | 5.42          | 16.16           | 15.57           | 18.71          | 107 (60.8%)                     |
| <b>1.63</b>   | 1.63   | 1.99                                 | (41.5)        | (42%)                   | (95.95)       | (1.70)                            | 105                               |                                    |                          | (6)            | (5.51)         | (2.49)        | (8.9)           | (5.55)          | (3.24)         |                                 |
| <b>[0.62–16.5]</b>  | <b>[0.62–9.65]</b>                                     | <b>[0.2–31.14]</b>                   |               |                         |               | <b>104</b>                        | (62.1%)                           |                                    |                          |                |                |               |                 |                 |                |                                 |
| <b>SSD with pain 36(15%)</b>  |  |                                      |               |                         |               |                                   |                                   |                                    |                          |                |                |               |                 |                 |                |                                 |
| <b>10.7 (41.55)</b>   | 2.41 (1.44)  | 4.24 (4.9)                           | 42.78         | 13                      | 85.84         | <b>1.81</b>                       | 2.17 (2.32)                       | <b>13 (36.1%)</b>                  | 5 (14.7%)                | 15.56          | 12.59          | <b>7.25</b>   | 19.06           | 16.97           | 20.11          | 20 (55.6%)                      |
| <b>2.01</b>   | 1.96   | 2.55                                 | (14.28)       | (36.1)                  | (94.56)       | <b>(2.05)</b>                     | 24 (66.7%)                        |                                    |                          | (5.93)         | (5.19)         | <b>(1.86)</b> | (8.04)          | (5.28)          | (2.42)         |                                 |
| <b>[1.07–226]</b>   | <b>[1.07–7.08]</b>                                     | <b>[0.2–23.41]</b>                   |               |                         |               | <b>23</b>                         | (63.9%)                           |                                    |                          |                |                |               |                 |                 |                |                                 |
| <b>Illness anxiety 15(6%)</b>                                       |  |                                      |               |                         |               |                                   |                                   |                                    |                          |                |                |               |                 |                 |                |                                 |
| <b>2.22 (1.5)</b>   | 2.22 (1.5)   | 2.59 (3.18)                          | 43.6          | 7 (46.7)                | 92.27         | <b>0.36</b>                       | 1.14 (1.41)                       | <b>1 (7.1%)</b>                    | 0 (0%)                   | 11.17          | 9.92           | <b>4.31</b>   | 12.46           | 13              | 18.07          | 7 (46.7%)                       |
| <b>1.93</b>   | 1.93   | 1.74                                 | (14.01)       |                         | (91.59)       | <b>(0.63)</b>                     | 7 (50%)                           |                                    |                          | (6.1)          | (4.35)         | <b>(2.36)</b> | (7.4)           | (4.51)          | (3.75)         |                                 |
| <b>[0.62–5.24]</b>  | <b>[0.62–5.24]</b>                                     | <b>[0.2–1.72]</b>                    |               |                         |               | <b>4</b>                          | (28.6%)                           |                                    |                          |                |                |               |                 |                 |                |                                 |
| <b>Conversion Disorder (CD) 14(6%)</b>                              |  |                                      |               |                         |               |                                   |                                   |                                    |                          |                |                |               |                 |                 |                |                                 |
| <b>5.88 (13.32)</b>   | 2.05 (1.32)  | 3.98 (4.64)                          | 39            | 3                       | 71.92         | 1.43                              | 2.5 (3.13)                        | <b>6 (42.9%)</b>                   | 1 (9.1%)                 | 12.83          | 10.57          | 5.54          | 15.21           | 13.64           | 17.57          | 8 (57.1%)                       |
| <b>1.71 [</b>   | 1.52   | 2.71                                 | (14.43)       | (21.4%)                 | (59.37)       | (1.4)                             | 8 (57.1%)                         |                                    |                          | (7.8)          | (5.18)         | (2.76)        | (11.52)         | (6.62)          | (4.89)         |                                 |
| <b>0.87–48]</b>   | <b>[0.87–4.58]</b>                                     | <b>[0.23–17.15]</b>                  |               |                         |               | <b>9</b>                          | (64.3%)                           |                                    |                          |                |                |               |                 |                 |                |                                 |
| <b>p-value for variable differences between the SSRD categories</b> |  |                                      |               |                         |               |                                   |                                   |                                    |                          |                |                |               |                 |                 |                |                                 |
| 0.315   | 0.556  | 0.585                                | 0.808         | 0.422                   | 0.799         | <b>0.004</b>                      | 0.566                             | <b>0.015</b>                       | 0.368                    | 0.221          | 0.373          | <b>0.001</b>  | 0.071           | 0.185           | 0.157          | 0.712                           |

**Table 3**

Clinical characteristics in SSRD patients with comorbid CMC versus no comorbid CMC.

| Comorbid CMC N = 142       |                     |              |             | No Comorbid CMC N = 99     |                      |              |            | p-value           |
|----------------------------|---------------------|--------------|-------------|----------------------------|----------------------|--------------|------------|-------------------|
| Variable N                 | M(SD) Median        | Range        | N (%)       | Variable N                 | M(SD) Median         | Range        | N (%)      |                   |
| IL-6                       | 2.4 (2.47)          | 0.62–19.4    | Elevated*   | IL-6                       | 5.33 (25.07)         | 0.82–226     | Elevated*  | 0.842             |
| 123                        | 1.64                |              | 43 (35%)    | 83                         | 1.77                 |              | 29 (34.9%) |                   |
| IL-6 with outliers removed | 2.14 (1.43)         | 0.62–8.46    | 41 (33.9%)  | IL-6 with outliers removed | 2.08 (1.36)          | 0.82–9.65    | 27         | 0.758             |
| 121                        | 1.63                |              |             | 81                         | 1.76                 |              | (33.3%)    |                   |
| hsCRP                      | 3.81 (4.91)         | 0.2–31.14    | 49 (36.3%)  | hsCRP                      | 3.45 (3.97)          | 0.2–22.11    | 38 (39.2%) | 0.784             |
| 135                        | 2.22                |              |             | 97                         | 1.99                 |              |            |                   |
| Age                        | <b>44.8 (13.12)</b> | <b>18–80</b> | <b>NA</b>   | Age                        | <b>38.73 (13.12)</b> | <b>15–78</b> | <b>NA</b>  | <b>&lt; 0.001</b> |
| 142                        | <b>44</b>           |              |             | 99                         | <b>35</b>            |              |            |                   |
| Gender                     | NA                  | NA           | 58 (40.8%)  | Gender                     | NA                   | NA           | 39 (39.4%) | 0.821             |
| 142                        |                     |              |             | 99                         |                      |              |            |                   |
| Male N (%)                 |                     |              |             |                            |                      |              |            |                   |
| LCU                        | 96.09 (103.07)      | 0–545        | NA          | LCU                        | 87.31 (78.02)        | 0–374        | NA         | 0.993             |
| 116                        | 67.5                |              |             | 85                         | 72                   |              |            |                   |
| PHQ9                       | 14.33 (6.21)        | 0–27         | NA          | PHQ9                       | 14.24 (6.04)         | 0–27         | NA         | 0.866             |
| 135                        | 14                  |              |             | 92                         | 14                   |              |            |                   |
| GAD7                       | 11.4 (5.54)         | 0–21         | NA          | GAD7                       | 11.9 (5.17)          | 1–21         | NA         | 0.567             |
| 136                        | 11                  |              |             | 94                         | 11                   |              |            |                   |
| BPI                        | 5.84 (2.45)         | 0–10         | 121 (87.7%) | BPI                        | 5.36 (2.58)          | 0–10         | 74 (82.2%) | 0.116             |
| 138                        | 6.5                 |              |             | 90                         | 6                    |              |            |                   |
| PSQ51                      | 17.02 (9.28)        | 1–45         | NA          | PSQ51                      | 15.37 (8.35)         | 0–42         | NA         | 0.186             |
| 136                        | 17                  |              |             | 93                         | 14                   |              |            |                   |
| PHQ15                      | 15.51 (5.59)        | 5–28         | NA          | PHQ15                      | 15.54 (5.57)         | 0–30         | NA         | 0.958             |
| 137                        | 15                  |              |             | 93                         | 15                   |              |            |                   |
| SF36                       | <b>19.27 (3.45)</b> | <b>8–25</b>  | <b>NA</b>   | SF36                       | <b>18.15 (3.01)</b>  | <b>6–24</b>  | <b>NA</b>  | <b>0.002</b>      |
| 140                        | <b>20</b>           |              |             | 94                         | <b>18</b>            |              |            |                   |
| Childhood Sexual Abuse     | NA                  | NA           | 34 (23.9%)  | Childhood sexual abuse     | NA                   | NA           | 19 (19.6%) | 0.426             |
| 142                        |                     |              |             | 97                         |                      |              |            |                   |
| Adult sexual Abuse         | NA                  | NA           | 8 (7.1%)    | Adult sexual abuse         | NA                   | NA           | 8 (9.8)    | 0.501             |
| 113                        |                     |              |             | 82                         |                      |              |            |                   |
| ACE                        | 1.6 (1.88)          | 0–8          | 85 (61.2%)  | ACE                        | 1.98 (2.36)          | 0–10         | 59 (62.8%) | 0.379             |
| 139                        | 1                   |              |             | 94                         | 1                    |              |            |                   |
| AAE                        | 1.35 (1.6)          | 0–7          | 82 (59%)    | AAE                        | 1.64 (1.88)          | 0–8          | 58 (61.7%) | 0.335             |
| 139                        | 1                   |              |             | 94                         | 1                    |              |            |                   |

\* Elevated IL-6 score = score 2.056 or higher as indicated in results section 4.4.

variable was categorical. We dealt with missing data by using pairwise deletion.

### 3. Results

Table 2 shows the clinical and demographic characteristics and p-values for the sample as a whole and for the different SSRD classifications.

The mean level of IL-6 in the total sample was 3.58 (16.03) with median 1.65 pg/ml and range 0.62–226. Seventy-two (35%) of the patients had elevated IL-6. After outlier removal (4 IL-6 values), mean IL-6 level was 2.12 (1.4) pg/ml, median remained the same, 1.65 pg/ml, and the range was 0.62–9.65 pg/ml. Mean hsCRP level was 3.66 (4.54) mg/l; median 2.17, range 0.2–31.14. 37.5% of the patients have an hsCRP level higher than 3.0 mg/l. No outliers in hsCRP level were detected. There were no significantly different levels of IL-6 or hsCRP, prevalence of comorbid chronic medical conditions, or ACE in the different SSRD classifications. However, adult traumatic experiences (AAE) occurred in over 60% of all SSRD categories, except illness anxiety, which had significantly less AAE (28.6%;  $p = .004$ ). Childhood sexual abuse occurred in only 7.1% of patients with illness anxiety, but significantly more often in SSD with pain (36.1%) and with CD/FND (42.9%) ( $p = .015$ ). Expectedly, high pain score (BPI) occurred significantly more often in SSD with pain. Regarding sexual revictimization, childhood sexual abuse was reported in 53 (22.2%) of the sample. In patients with childhood sexual abuse, 21.4% reported adult sexual abuse versus 4.6% in patients without childhood sexual abuse ( $\chi^2(1) = 12.427$ ,  $p = .001$ ,  $\phi = .252$ ).

Table 3 shows the clinical and demographic characteristics of the sample divided as SSRD with comorbid chronic medical conditions versus without comorbid chronic medical conditions.

There were no significant differences in terms of IL-6 or hsCRP levels between patients with versus those without comorbid chronic medical conditions. The only significant differences concerned age ( $p < .0001$ ) and perceived general health ( $p = .002$ ). Patients with chronic medical conditions were on average six years older, with an average of 44.8 years compared to 38.7 (13.12) in the group without comorbid chronic medical conditions. The SF36 general health score was significantly higher in the patients with comorbid chronic medical conditions, with a score of 19.27 (3.45) versus 18.15 (3.01) in the patients with SSRD with unexplained medical symptoms.

Table 4 shows the associations between IL-6 and hsCRP levels (continuous) and clinical variables over the whole sample.

IL-6 was associated with age, but hsCRP was not. Robust regression analysis yielded a Beta of .022 (95%CI = 0.012–0.032), meaning that for every year of an increase in age, there was a predicted increase in IL-6 of 0.022 pg/ml. IL-6 and hsCRP were both associated with pain. hsCRP was associated with the number of somatic symptoms (PSQ51 and PHQ15) and was negatively associated with a comorbid autism spectrum disorder.

IL-6 and hsCRP levels (continuous) were associated (Kendall's  $\tau = 0.223$ ,  $p < .001$ ). After the exclusion of the four outliers, the association between IL-6 and hsCRP levels (continuous) was Kendall's  $\tau = 0.249$ ,  $p < .001$ .

An IL-6 value of 2.01 pg/ml corresponded with the percentage of patients with a hsCRP level of 3.0 mg/l or higher. As the second step, assuming that a hsCRP of 3.0 mg/l or higher is an elevated hsCRP level (Ridker, 2016), and after removing the outliers, we found that a hsCRP level of 3 mg/l predicted an IL-6 level of 2.056 pg/ml in a regression analysis (95%CI around prediction: 1.864–2.249).

We then explored if levels of hsCRP  $\geq 3.0$  mg/l and IL-6  $\geq 2.056$  pg/ml were associated with particular clinical characteristics for which they



**Table 4**

Associations between IL6 and hsCRP and comorbid CMCs, ACE and recent stress, and other clinical variables.

| Variable                | IL-6                               | hsCRP                                |
|-------------------------|------------------------------------|--------------------------------------|
| Age                     | $\tau = .26, z = 5.53, p < .001$   | $\tau = .04, z = 0.91$<br>$p = .364$ |
| Gender                  | $\tau = .00, z = -0.03, p = .978$  | $\tau = -.05, z = -1.00, p = .317$   |
| LCU                     | $\tau = -.07, z = -1.38, p = .168$ | $\tau = .06, z = 1.20, p = .232$     |
| SSRDcat                 | $p = 0.419$                        | $p = 0.579$                          |
| Somatic                 | $\tau = .01, z = 0.20, p = .841$   | $\tau = .01, z = 0.28, p = .783$     |
| PHQ9                    | $\tau = .09, z = 1.91, p = .056$   | $\tau = .07, z = 1.47, p = .143$     |
| GAD7                    | $\tau = .03, z = 0.65, p = .514$   | $\tau = .04, z = 0.80, p = .425$     |
| BPI                     | $\tau = .11, z = 2.13, p = .033$   | $\tau = .14, z = 2.87, p = .004$     |
| PSQ51                   | $\tau = .08, z = 1.64, p = .102$   | $\tau = .12, z = 2.54, p = .011$     |
| PHQ15                   | $\tau = .04, z = 0.88, p = .379$   | $\tau = .11, z = 2.46, p = .014$     |
| SF36                    | $\tau = .04, z = 0.76, p = .449$   | $\tau = .05, z = 1.04, p = .299$     |
| Childhood Sexual Trauma | $\tau = .08, z = 1.45, p = .146$   | $\tau = .09, z = 1.72, p = .085$     |
| Adult sexual trauma     | $\tau = .08, z = 1.20, p = .232$   | $\tau = -.07, z = -1.21, p = .224$   |
| ACE                     | $\tau = .05, z = 0.90, p = .370$   | $\tau = .05, z = 1.09, p = .277$     |
| AAE                     | $\tau = .05, z = 0.90, p = .370$   | $\tau = .01, z = 0.26, p = .792$     |
| Co_Dep                  | $\tau = .02, z = 0.28, p = .780$   | $\tau = .06, z = 1.03, p = .305$     |
| Co_GenAnx               | $\tau = -.03, z = -0.55, p = .581$ | $\tau = -.04, z = -0.78, p = .437$   |
| Co_PanDis               | $\tau = -.04, z = -0.72, p = .474$ | $\tau = -.02, z = -0.44, p = .656$   |
| Co_PTSS                 | $\tau = .05, z = 0.82, p = .414$   | $\tau = .05, z = 0.84, p = .401$     |
| Co_PersDis              | $\tau = -.01, z = -0.17, p = .869$ | $\tau = -.06, z = -1.14, p = .254$   |
| Co_ADHD                 | $\tau = -.03, z = -0.46, p = .647$ | $\tau = -.06, z = -1.20, p = .228$   |
| Co_Aut                  | $\tau = -.06, z = -1.03, p = .303$ | $\tau = -.14, z = -2.68, p = .007$   |
| Co_OCD                  | $\tau = -.06, z = -1.04, p = .297$ | $\tau = .05, z = 0.91, p = .365$     |
| Co_Anx_comb*            | $\tau = -.02, z = -0.27, p = .788$ | $\tau = .01, z = 0.20, p = .839$     |

\* General Anxiety disorder, Panic Disorder, PTSS, and/or OCD as comorbidity.

could be used as biomarkers. A sensitivity analysis removing the IL-6 outliers was performed and the p-values for differences between elevated and non-elevated IL-6 levels are shown in Table 5.

**Table 5**

Clinical characteristics in elevated IL-6 compared to not elevated IL-6 after sensitivity analysis.

| Variable                | High IL-6                     | N (%)      | N  | Low IL-6                       | N (%)       | N   | p value |
|-------------------------|-------------------------------|------------|----|--------------------------------|-------------|-----|---------|
| hsCRP                   | 4.87 (5.2); 2.86; [0.2–31.14] | 34 (48.6%) | 70 | 2.88 (3.86); 1.24; [0.2–23.41] | 37 (28.2%)  | 131 | <0.001  |
| Age                     | 47.14 (11.5); 47; [19–78]     | NA         | 72 | 39.68 (13.61); 38; [15–78]     | NA          | 134 | <0.001  |
| Gender                  | NA                            | 28 (38.9%) | 72 | NA                             | 55 (41%)    | 134 | 0.764   |
| LCU                     | 85.52 (91.12); 65.5; [0–501]  | NA         | 58 | 96.95 (95.52); 78; [0–545]     | NA          | 116 | 0.415   |
| Somatic comorbidity     | NA                            | 43 (59.7%) | 72 | NA                             | 80 (59.7%)  | 134 | 0.998   |
| PHQ9                    | 15.53 (6.45); 16; [0–27]      | NA         | 70 | 13.74 (6.04); 14; [0–27]       | NA          | 126 | 0.058   |
| GAD7                    | 12.3 (5.49); 13; [1–21]       | NA         | 70 | 11.34 (5.31); 11; [1–21]       | NA          | 128 | 0.220   |
| BPI                     | 6.11 (2.23); 6; [0–10]        | 64 (91.4%) | 70 | 5.5 (2.54); 6; [0–10]          | 107 (84.3%) | 127 | 0.146   |
| PSQ51                   | 18.81 (9.09); 17; [4–45]      | NA         | 69 | 15.55 (8.85); 15; [0–36]       | NA          | 128 | 0.016   |
| PHQ15                   | 16.29 (5.28); 16; [5–27]      | NA         | 68 | 15.35 (5.81); 15; [0–30]       | NA          | 130 | 0.236   |
| SF36                    | 19.41 (3.04); 20; [13–25]     | NA         | 71 | 18.57 (3.47); 19; [6–25]       | NA          | 129 | 0.170   |
| Childhood Sexual Trauma | NA                            | 22 (30.6%) | 72 | NA                             | 24 (18.2%)  | 132 | 0.112   |
| Adult sexual Trauma     | NA                            | 8 (13.6%)  | 59 | NA                             | 8 (7.8%)    | 103 | 0.234   |
| ACE                     | 2.23 (2.38); 1; [0–9]         | 49 (70%)   | 70 | 1.57 (1.91); 1; [0–10]         | 79 (60.8%)  | 130 | 0.064   |
| AAE                     | 1.87 (2.12); 1; [0–8]         | 45 (64.3%) | 70 | 1.35 (1.5); 1; [0–6]           | 80 (61.5%)  | 130 | 0.230   |

Patients with elevated IL-6, i.e. levels of 2.056 pg/ml or higher, had significantly higher hsCRP: 4.87 (5.2) mg/l in the elevated IL-6 group versus 2.88 (3.86) mg/l in the non-elevated IL-6 group ( $p < .001$ ). The mean age was 47.14 (11.5) in the elevated IL6 group versus 39.68 (13.61) in the non-elevated IL6 group, a difference of 8 years ( $p < .001$ ). The elevated IL-6 group also showed significantly higher somatic symptom levels (PSQ51 mean 18.81 (9.09) versus 15.55 (8.85),  $p = .016$ ).

Findings for hsCRP after sensitivity analysis with reported means and SDs of IL-6 without the outlying IL-6 values are presented in Table 6.

Patients with elevated hsCRP, i.e. a level of 3.0 mg/l or higher, had significantly higher IL-6 (2.52 (1.59) pg/ml) versus 1.89 (1.26) pg/ml in the non-elevated hsCRP group ( $p < .001$ ). They scored (marginal) significantly higher on BPI (6.3 (2.24) versus 5.18 (2.59),  $p = .002$ ) and on somatic symptoms (PSQ51 mean 18.27 (9.69) versus 15.38 (8.29),  $p = .038$ ; PHQ15 mean 16.7 (5.63) versus 14.94 (5.41),  $p = 0.038$ ). Elevated hsCRP was significantly associated with childhood sexual abuse: 31% of 87 patients with elevated hsCRP had a history of childhood sexual abuse, versus 18.1% with non-elevated hsCRP ( $p = .042$ ).

#### 4. Discussion

This study for the first time investigates IL-6 and hsCRP in a large sample of patients with SSRD and demonstrates high levels indicating SLI. It shows that IL-6 and hsCRP do not differentiate between SSRD subclassifications such as SSD with pain, CD/FND and illness anxiety. Also, its innovative design and abundance of data allows for establishing that comorbid chronic medical conditions, general adverse childhood events, and current stress are not associated with IL-6 and hsCRP levels. We suggest that in clinical research, elevated IL-6 and hsCRP can be used as biomarkers for SLI and can indicate risk for childhood sexual abuse in SSRD. Elevated hsCRP may also indicate risk for comorbid depression or high pain levels in SSRD. We establish cut-off scores for the first time that may be used in future clinical research.

The results show a mean IL-6 level of 3.58 (16.03) pg/ml and with correction for outliers this is 2.12 (1.4) pg/ml. hsCRP mean is 3.66 (4.54) mg/l, which is above the cut-off recommended by the American Heart Association for increased risk of cardiovascular events and SLI. The mean IL-6 level is higher than the cut-off of 2.056 pg/ml predicted by a hsCRP of 3.0 mg/l in our study. These levels are higher than in a study in the Swedish general population (Garvin et al., 2016), higher than in a general population study in Manhattan (Luna et al., 2014) and much higher than in an elderly general population sample in rural Iowa although the mean age in the elderly sample is higher than in our study (Harris et al., 1999). Also, the median of IL-6 and hsCRP in our study is higher than the median in a UK study in civil servants in London (Cho et al., 2013). The high levels of hsCRP and IL-6 in our sample fit a clinical population rather than a general population sample and seem to be indicative of SLI in SSRD.

In this sample of patients with SSRD, 142 (58.9%) of the patients had

**Table 6**

Clinical characteristics elevated hsCRP versus non-elevated hsCRP after removal of IL-6 outliers.

| Variable                    | High hsCRP                           | N percentage           | N  | Low hsCRP                             | Low Percentage    | N   | p value           |
|-----------------------------|--------------------------------------|------------------------|----|---------------------------------------|-------------------|-----|-------------------|
| <b>IL6_outliers removed</b> | <b>2.52</b> (1.59); 1.98; [0.7–9.65] | 33 (47.1%)             | 70 | <b>1.89</b> (1.26); 1.48; [0.62–8.46] | 33 (26%)          | 127 | <b>&lt; 0.001</b> |
| <b>Age</b>                  | 41.31 (13.28); 41; [18–72]           | NA                     | 87 | 42.67 (13.27); 41; [15–78]            | NA                | 145 | 0.563             |
| <b>Gender</b>               | NA                                   | 33 Male (37.9%)        | 87 | NA                                    | 57 (39.3%)        | 145 | 0.835             |
| <b>LCU</b>                  | 102.04 (95.63); 80; [0–545]          | NA                     | 72 | 87.8 (93.76); 64.5; [0–501]           | NA                | 122 | 0.132             |
| <b>Somatic comorbidity</b>  | NA                                   | 49 (56.3%)             | 87 | NA                                    | 86 (59.3%)        | 145 | 0.655             |
| <b>PHQ9</b>                 | <b>15.23</b> (5.74); 15; [4–27]      | NA                     | 83 | <b>13.7</b> (6.16); 13; [0–27]        | NA                | 135 | <b>0.030</b>      |
| <b>GAD7</b>                 | 12.28 (5.27); 13; [0–21]             | NA                     | 82 | 11.23 (5.38); 11; [1–21]              | NA                | 139 | 0.141             |
| <b>BPI</b>                  | <b>6.3</b> (2.24); 7; [0–10]         | 77 elevated BPI(92.8%) | 83 | <b>5.18</b> (2.59); 5; [0–10]         | 110 (80.3%)       | 137 | <b>0.002</b>      |
| <b>PSQ51</b>                | <b>18.27</b> (9.69); 16; [1–45]      | NA                     | 81 | <b>15.38</b> (8.29); 15; [0–36]       | NA                | 140 | <b>0.038</b>      |
| <b>PHQ15</b>                | <b>16.7</b> (5.63); 18; [5–30]       | NA                     | 83 | <b>14.94</b> (5.41); 14; [0–27]       | NA                | 139 | <b>0.038</b>      |
| <b>SF36</b>                 | 19.33 (3.2); 19.5; [10–25]           | NA                     | 84 | 18.47 (3.34); 19; [6–25]              | NA                | 142 | 0.066             |
| <b>Childhood</b>            |                                      |                        |    |                                       |                   |     |                   |
| <b>Sexual_Trauma</b>        | NA                                   | 27 (31%)               | 87 | NA                                    | <b>26 (18.1%)</b> | 144 | <b>0.042</b>      |
| <b>ACE</b>                  | 2.08 (2.35); 1; [0–9]                | 52 (62.7%)             | 83 | 1.64 (1.93); 1; [0–10]                | 91 (64.1%)        | 142 | 0.356             |
| <b>AAE</b>                  | 1.57 (1.88); 1; [0–8]                | 49 (59%)               | 83 | 1.46 (1.65); 1; [0–7]                 | 88 (62%)          | 142 | 0.974             |
| <b>Co_Aut</b>               | NA                                   | 2 (2.3%)               | 87 | NA                                    | 13 (9%)           | 145 | 0.116             |

comorbid chronic medical conditions. There were no significant differences between SSRD classifications or patients with and without comorbid chronic medical conditions in terms of IL-6 or hsCRP levels. This suggests that SLI, which is not related to comorbid chronic medical conditions, may be an underlying mechanism, and that IL-6 and hsCRP are indicators of a direct pathophysiologic mechanism related to SLI in SSRD. The finding that both IL-6 and hsCRP are not associated with comorbid chronic medical conditions suggest that both are biomarkers reflecting SLI in SSRD.

All SSRD classifications showed a mean pain level above the cut-off score of  $\geq 3$  for clinically relevant pain on the BPI (Brecht et al., 2007), ranging between 4.31 in Illness Anxiety and 7.25 in SSD with pain. The mean IL-6 level in SSD with pain in our sample is approximately twice as high than in a sample of fibromyalgia patients (Mendieta et al., 2016). As the association between IL-6 and level of pain that we found cannot be explained by comorbid chronic medical conditions, a logical explanation might be that pain is a cytokine-related effect, as our findings suggest a role of SLI in the pathogenesis of nonspecific pain in SSRD. This is in line with a number of studies suggesting IL-6 plays a role in pain disorders, including fibromyalgia (Andrés-Rodríguez et al., 2019; Uçeyler et al., 2011). The pathophysiological role of cytokines in fibromyalgia is still unclear. One mechanism might be that IL-6 sensitizes pain receptors, although that would be at the cellular level and would not concern IL-6 in the circulation (Atzeni et al., 2019). Other studies suggest that prolonged sickness behaviour could be the underlying mechanism in the association between hsCRP, pain and depression. Also, It could be that pain and sleep disturbance are mediators of increased inflammatory activity, rather than pain being a consequence of increased inflammatory activity (Allen et al., 2020; Haack et al., 2007; Quartana et al., 2015). Unfortunately, we do not have data on sleep patterns to explore that in this dataset.

The average ACE score is 1.75, and 61.8% of the patients report ACE, which is almost similar to the 64% reported in the original ACE field study amongst 17,000 people visiting a medical evaluation centre in the USA. (Desai et al., 2002) However, the ACE scores in our study are lower than the 77% prevalence of ACE reported in specialty mental health outpatients with anxiety and depressive disorders (van der Feltz-Cornelis et al., 2019a).

Childhood sexual abuse was reported in 22.2% of the whole sample. We found high AAE levels and high rates of childhood sexual abuse, especially in SSD with pain and in CD/FND. Childhood sexual abuse was associated with adult sexual abuse in 21.4% of cases; therefore, sexual revictimization occurred in one in 5 cases of childhood sexual abuse. This rate is lower than in Australian community studies reporting approximately 35% revictimization (Werner et al., 2016), and in a study in specialty mental health outpatients with anxiety and depressive disorder in the Netherlands reporting 42% sexual revictimization (van der Feltz-Cornelis et al., 2019a). Therefore, the question arises whether there

might be a particular mechanism that sparks the development of SLI and CD/FND after experiencing childhood sexual abuse and whether that involves sexual revictimization.

Both elevated hsCRP and elevated IL-6 are associated with childhood sexual abuse. Childhood sexual abuse contributes to psychological trauma and its consequences. Maybe sexual abuse in a child would be associated with physical injury and the deposit of body material or other substances in the body of the child, and hypothetically this might induce immunological reactions that might have effects into adulthood. However, this has so far not been explored. We found that sexual revictimization occurs in 1 in 5 patients with childhood sexual abuse in this sample; however, the analysis showed no association between hsCRP and adult sexual abuse, so that would not be an explanation. Baumeister et al. found elevated IL-6 and hsCRP in childhood trauma (2016) and proposed that somatic comorbidity or comorbid depression or different kinds of trauma might play a role in this. However, we did not find an association with general childhood trauma other than sexual trauma, and not with comorbid chronic medical conditions. Also, although mean levels of anxiety are at the clinical level in our sample, the association between hsCRP ( $p = .029$ ) or IL-6 ( $p = .066$ ) and childhood sexual abuse remained significant after controlling for PTSD or GAD7. Hence our study does not support a role for anxiety or comorbid PTSD as explanation of elevated hsCRP or IL-6 in case of childhood sexual abuse by anxiety or comorbid PTSD in SSRD. Cellular pathways may be involved. T cell expression has been found to be elevated in women with PTSD who experienced childhood sexual abuse independently of norepinephrine or cortisol levels (Lemieux et al., 2008). Future research should explore this pathogenic mechanism further. IL-6 and hsCRP were associated with each other with a medium effect size. This leaves room for other mechanisms affecting their association. There may be several possible explanations for this. Research suggests that, although hsCRP is associated with IL-6 and can predict cardiovascular risk (Koenig et al., 1999), being an acute phase protein produced in the liver after activation by IL-6 (Volanakis, 2001), it might not be the most eligible biomarker for chronic SLI, whereas IL-6 plays a role in both acute phase and chronic inflammatory processes, as well as in autoimmunity, via various pathways (Tanaka et al., 2014). Another explanation might be that IL-6 and hsCRP might be biomarkers for SLI in slightly different patient profiles. Although the underlying mechanism needs to be elucidated further, this study suggests that elevated IL-6 and hsCRP can be used as biomarkers for SLI in SSRD independently of comorbid chronic medical conditions. They can also indicate risk for childhood sexual abuse in SSRD and elevated hsCRP can indicate risk for comorbid depression or high pain levels in SSRD as well. Both hsCRP and IL-6 have been identified as reliable biomarkers for inflammation, indicating different parts of the inflammation pathway, by the Centers for Disease Control and Prevention and the American Heart Association (Pearson et al., 2003), in a scientific statement in which they



guided the possibilities and pitfalls of clinical use as biomarkers. They also indicated which would be useful for use as cardiovascular clinical risk biomarker, and which for other conditions. In terms of cut-off levels, based upon the results, we found an IL-6 level of 2.056 pg/ml corresponding with a hsCRP level of 3.0 mg/l. To take lab variety into account, we suggest using a cut-off for IL-6 of 2.0 pg/ml. This would enable us to conduct future research applying and validating those cut-offs for profiling studies. (van der Feltz-Cornelis, 2020).

#### 4.1. Strengths and limitations

This is an innovative study which attempted to approach the question of SLI in SSRD in a clinical sample and to explore clinical relevance and possible diagnostic value of IL-6 and hsCRP. The sample size was large and the wealth of systematically assessed clinical data enabled us to explore the influence of demographic and clinical characteristics, including several aspects of trauma and stress, as well as somatic and psychiatric comorbidity on the association between IL-6, hsCRP and several SSRD categories. We shed light on the extent to which SLI might play a role in SSD, SSD with pain, CD/FND and illness anxiety, and this opens avenues for further research. The finding that IL-6 and hsCRP levels were associated with pain and somatic symptoms but were not associated with comorbid chronic medical conditions is of high clinical relevance. The finding that hsCRP and IL-6 are associated with childhood sexual abuse in SSRD indicates the possibility to use both to discern a patient profile combining SLI and childhood sexual abuse in SSRD. Elevated hsCRP also seems to discern pain and comorbid depression states with SLI in SSRD. Furthermore, we were able to suggest a cut-off level for IL-6 to be used as a biomarker in SSRD, something that so far has not been done, that can be validated in further research, and that opens the avenue of conducting clinical profiling studies. All of these can be considered strengths of our study. There are, however, also limitations. The cross-sectional, observational design does not allow controlling for confounders for which data are not available, as could be done in an experimental randomised controlled design. Smoking (Zevin et al., 2001) and obesity (Yudkin et al., 1999) are known to be of influence on SLI, but we had no data on these variables available in this sample. Our study sample provides the opportunity to make an intragroup comparison only, as we cannot compare with healthy controls from the same region. The latter would be relevant in terms of generalisability of our findings, as there might be uncontrollable associations with local environmental factors, including water, food, pollution, and climate conditions, that might play a role in cytokine levels in a given population. Other limitations are that some of the SSRD types had rather small numbers of patients. Also, this is a sample of patients with longstanding SSRD symptoms who visited a clinical centre of excellence that provides treatment to the 5% most complex patients in the Netherlands (Van Eck van der Sluijs et al., 2017). Hence, this study provides us with knowledge about the levels of SLI and the use of IL-6 and hsCRP as clinical biomarkers in chronic long-term cases of SSRD; this cannot automatically be generalized to SSRD in general.

#### 4.2. Recommendations for research

Longitudinal studies are needed that explore a possible temporal association between IL-6 or hsCRP, pain levels, childhood sexual abuse and treatment outcome in SSRD. This program of research should enable us to describe patient profiles (van der Feltz-Cornelis, 2020) that may benefit from different treatment provisions for SSRD, taking clinical characteristics and biomarkers into account. To this end, a personalised medicine approach for SSRD might be developed.

#### 5. Conclusion

IL-6 and hsCRP levels are substantially higher in SSRD compared to the general population and to fibromyalgia patients. IL-6 and hsCRP

indicate SLI in SSRD independently of comorbid chronic medical conditions. In terms of cut-off levels, based upon the results, we found an IL-6 level of 2.056 pg/ml corresponding with a hsCRP level of 3.0 mg/l. In clinical research, elevated IL-6 and hsCRP can be used as biomarkers for SLI and can indicate risk for childhood sexual abuse in SSRD. Elevated hsCRP may also be used as a biomarker indicating risk for comorbid depression or high pain levels in SSRD. Further high-quality longitudinal studies are needed to confirm these findings and to evaluate the magnitude of these associations.

#### Statement of ethics

The research was conducted ethically in accordance with the World Medical Association Declaration of Helsinki. No informed consent was required, as for the present research we used data that were collected for administrative purposes and monitoring of treatment outcome by treatment providers. According to Dutch law, in accordance with the Helsinki Declaration, and according to the Dutch Central Medical Ethical Committee, no explicit informed consent is required for the use of clinical or administrative data, collected in the context of treatment provision. At intake at CLGG, patients were informed that Patient Reported Outcome Measures (PROM) and medical data obtained during intake and treatment could be used for research evaluation on an anonymous basis, unless they indicated their dissent. In case of dissent, this was notified in the patient file. Patient files of dissenting patients were excluded from the study. Data were coded in order to create an anonymous dataset. The research protocol was approved by the scientific committee of GGz Breburg (2019-01).

#### Funding sources

GGz Breburg funded and supported the study. The funder had no influence on the design and conduct of the study, the preparation and analysis of the data and the interpretation and description of the results.

#### Data availability statement

The data are owned by a third party, GGz Breburg, that does not publicly share data. However, interested parties will be able to obtain data upon request as follows. Researchers can submit a research plan, which describes the background and methods of a proposed research question, and a request for specific data of the database used for this study to answer the research question. After approval of the research plan by the principal investigator and the director of GGz Breburg, a de-identified minimal dataset can be obtained. Information can be requested by contacting the principal investigator.

#### Declaration of competing interest

The authors have no conflicts of interest to declare.

#### Acknowledgement

CLGG (GGz Breburg) funded and supported the study. Dilana Ozgul performed data-entry for this study. Star-SHL provided the labprotocol and arranged the lab assessments for this study.

#### List of abbreviations

|        |   |
|--------|---|
| AAE    | Adverse Adult Experiences                               |
| ACE    | Adverse Childhood Experiences                           |
| ACE-IQ | ACE International Questionnaire                         |
| ADHD   | Attention-Deficit Hyperactivity Disorder                |
| BPI    | Brief Pain Inventory                                    |
| CD/FND | conversion disorder/functional neurological disorder    |
| CLGG   | Clinical Centre of Excellence for Body, Mind and Health |

|           |  |
|-----------|--|
| CRP       | C-reactive protein   |
| DSM       | Diagnostic and Statistical Manual of Mental Disorders                      |
| ECBS      | Expert Committee on Biological Standardization                             |
| ELISA     | Enzyme-Linked Immunosorbent Assay  |
| GAD-7     | Generalized Anxiety Disorder Questionnaire 7 items for anxiety             |
| hsCRP     | high-sensitivity C-reactive protein  |
| ICD-10    | International Classification of Diseases 10th Edition                      |
| IL-6      | interleukin 6  |
| LCU       | Life Change Units: Holmes and Rahe Scale for current stressful life events |
| MINI      | Mini-International Neuropsychiatric Interview                              |
| MUS       | Medically Unexplained Symptoms   |
| PHQ-9     | Patient Health Questionnaire 9 items for depression                        |
| PSQ-51    | Physical Symptom Questionnaire – 51 items                                  |
| PHQ-15    | Patient Health Questionnaire – 15 items for physical symptoms              |
| PROM      | Patient Reported Outcome Measures  |
| PTSD      | Post Traumatic Stress Disorder   |
| SCID-2    | Structured Clinical Interview for DSM-IV Axis 2 Disorders                  |
| SF-36     | Short Form 36 items for general functioning                                |
| SLI       | Systemic Low-grade Inflammation  |
| SSD       | Somatic Symptom Disorders  |
| SSRD      | Somatic Symptom Disorder and related disorders                             |
| TNF alpha | Tumour Necrosis Factor alpha   |
| WHO       | World Health Organization  |

## References

- Aaronson, N.K., Muller, M., Cohen, P.D., Essink-Bot, M.L., Fekkes, M., Sanderman, R., Sprangers, M.A., te Velde, A., Verrips, E., 1998. Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. *J. Clin. Epidemiol.* 51 (11), 1055–1068, 1998 Nov.
- Allen, S.F., Gilbody, S., Atkin, K., van der Feltz-Cornelis, C.M., 2020. The associations between loneliness, social exclusion and pain in the general population: a N=502,528 cross-sectional UK Biobank study. *J. Psychiatr. Res.* 130, 68–74. <https://doi.org/10.1016/j.jpsychires.2020.06.028>.
- American Psychiatric Association, 2013. *Diagnostic And Statistical Manual Of Mental Disorders: DSM-5*, fifth ed. American Psychiatric Publishing, Arlington, VA.
- Anda, R.F., Felitti, V.J., 1998. The Adverse Childhood Experiences (ACE) Study: Bridging the Gap between Childhood Trauma and Negative Consequences Later in Life. Retrieved 23072020 from. <http://www.acestudy.org>.
- Andrés-Rodríguez, L., Borrás, X., Feliu-Soler, A., Pérez-Aranda, A., Angartia-Osorio, N., Moreno Peral, P., Montero-Marin, J., García-Campayo, J., Carvalho, A.F., Maes, M., Luciano, J.V., 2019. Peripheral immune aberrations in fibromyalgia: a systematic review, meta-analysis and meta-regression. *Brain Behav. Immun.* S0889–1591 (19), 31274–31277. <https://doi.org/10.1016/j.bbi.2019.12.020>.
- Andrés-Rodríguez, L., Borrás, X., Feliu-Soler, A., Pérez-Aranda, A., Rozadilla-Sacanel, A., Arranz, B., Montero-Marin, J., García-Campayo, J., Angartia-Osorio, N., Maes, M., Luciano, J.V., 2019. Machine learning to understand the immune-inflammatory pathways in fibromyalgia. *Int. J. Mol. Sci.* 20 (17), E4231. <https://doi.org/10.3390/ijms20174231> pii.
- Atzeni, F.N.V., Masala, I.F., Sarzi-Puttini, P., Bonitta, G., 2019. IL-6 Involvement in pain, fatigue and mood disorders in rheumatoid arthritis and the effects of IL-6 inhibitor sarilumab. *Pharmacol. Res.* 149, 104402. <https://doi.org/10.1016/j.phrs.2019.104402>.
- Baumeister, D., Akhtar, R., Ciufolini, S., Pariante, C.M., Mondelli, V., 2016. Childhood trauma and adulthood inflammation: a meta-analysis of peripheral C-reactive protein, interleukin-6 and tumour necrosis factor- $\alpha$ . *Mol. Psychiatr.* 21 (5), 642–649. <https://doi.org/10.1038/mp.2015.67>.
- Brecht, S., Courtecuisse, C., Debieve, C., Croenlein, J., Desai, D., Raskin, J., Petit, C., Demyttenaere, K., 2007. Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial. *J. Clin. Psychiatr.* 68 (11), 1707–1716.
- Cho, H.J., Kivimäki, M., Bower, J.E., Irwin, M.R., 2013. Association of C-reactive protein and interleukin-6 with new-onset fatigue in the Whitehall II prospective cohort study. *Psychological Medicine Care* 43 (8), 1773–1783. <https://doi.org/10.1017/S0033291712002437>.
- Dantzer, R., O'Connor, J., Freund, G.G., Johnson, R.W., Kelley, K.W., 2008. From inflammation to sickness and depression: when the immune system subjugates the brain. *Nat. Rev. Neurosci.* 9, 46–56.
- De Waal, M.W., Arnold, I.A., Eekhof, J.A.H., Van Hemert, A.M., 2004. Somatoform disorders in general practice: prevalence, functional impairment and comorbidity with anxiety and depressive disorders. *Br. J. Psychiatry* 184, 470–476.
- Del Grande da Silva, G., Wiener, C.D., Barbosa, L.P., Marlova Gonçalves Araujo, J., Lopez Molina, M., San Martin, P., Pierre Oses, J., Jansen, K., Dias de Mattos Souza, L., Azevedo da Silva, R., 2016. Pro-inflammatory cytokines and psychotherapy in depression: results from a randomized clinical trial. *J. Psychiatr. Res.* 75, 57–64.
- Desai, S., Arias, I., Thompson, M.P., Basile, K.C., 2002. Childhood victimization and subsequent adult revictimization assessed in a nationally representative sample of women and men. *Violence Vict.* 17 (6), 639–653.
- Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E.K., Lancot, K.L., 2010. A meta-analysis of cytokines in major depression. *Biol. Psychiatr.* 67, 446–457.
- Einvik, G., Vistnes, M., Hrubos-Strom, H., Randby, A., Namtvedt, S.K., Nordhus, I.H., Somers, V.K., Dammen, T., Omland, T., 2012. Circulating cytokine concentrations are not associated with major depressive disorder in a community-based cohort. *Gen. Hosp. Psychiatr.* 34, 262–267.
- Gabay, C., 2006. Interleukin-6 and chronic inflammation. *Arthritis Res. Ther.* 8 (Suppl. 2), S3.
- Gaines Das, R.E., Poole, S., 1993. The international standard for interleukin-6. Evaluation in an international collaborative study. *J. Immunol. Methods* 160 (2), 147–153. [https://doi.org/10.1016/0022-1759\(93\)90172-4](https://doi.org/10.1016/0022-1759(93)90172-4).
- Garratt, A.M., Ruta, D., Abdalla, M.I., Russell, I.T., 1994. SF 36 health survey questionnaire: II. Responsiveness to changes in health status in four common clinical conditions. *Qual. Health Care* 3, 186–192.
- Garvin, P., Nilsson, E., Ernerudh, J., Kristenson, M., 2016. The joint subclinical elevation of CRP and IL-6 is associated with lower health-related quality of life in comparison with no elevation or elevation of only one of the biomarkers. *Qual. Life Res.* 25 (1), 213–221. <https://doi.org/10.1007/s11136-015-1068-6>.
- Gouin, J.P., Caldwell, W., Woods, R., Malarkey, W.B., 2017. Resilience resources moderate the association of adverse childhood experiences with adulthood inflammation. *Ann. Behav. Med.* 51 (5), 782–786. <https://doi.org/10.1007/s12160-017-9891-3>.
- Grosse, L., Ambree, O., Jörgens, S., Jawahar, M.C., Singhal, G., Stacey, D., Arolt, V., Baune, B.T., 2016. Cytokine levels in major depression are related to childhood trauma but not to recent stressors. *Psychoneuroendocrinology* 73, 24–31. <https://doi.org/10.1016/j.psyneuen.2016.07.205>.
- Haack, M.S.E., Mullington, J.M., 2007. Elevated inflammatory markers in response to prolonged sleep restriction are associated with increased pain experience in healthy volunteers. *Sleep* 30 (9), 1145–1152. <https://doi.org/10.1093/sleep/30.9.1145>.
- Harris, T.B., Ferrucci, L., Tracy, R.P., Corti, M.C., Wacholder, S., Ettinger Jr., W.H., Heimovitz, H., Cohen, H.J., Wallace, R., 1999. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. *Am. J. Med.* 106 (5), 506–512. [https://doi.org/10.1016/s0002-9343\(99\)00066-2](https://doi.org/10.1016/s0002-9343(99)00066-2).
- Holmes, T.H., Rahe, R.H., 1967. The social readjustment rating scale. *J. Psychosom. Res.* 11, 213–218.
- Howren, Bryant M., Lamkin, D., Suls, J., 2009. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. *Psychosom. Med.* 71, 171–186.
- Huysse, F.J., Lyons, S.J., Stiefel, F.C., Slaets, J.P., de Jonge, P., Fink, P., Gans, R.O., Guex, P., Herzog, T., Lobo, A., Smith, G.C., van Schijndel, R.S., 1999. INTERMED: a method to assess health service needs. I. Development and reliability. *Gen. Hosp. Psychiatr.* 21 (1), 39–48.
- Koenig, W., Sund, M., Frohlich, M., Fisher, H.G., Lowel, H., Doring, A., Hutchinson, W.L., Pepys, M.B., 1999. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men. *Circulation* 99, 237–242.
- Kovacs, D., Eszlari, N., Petschner, P., Pap, D., Vas, S., Kovacs, P., Gonda, X., Bagdy, J., Juhász, G., 2016. Interleukin-6 promoter polymorphism interacts with pain and life stress influencing depression phenotypes. *J. Neural. Transm.* 123 (5), 541–548.
- Kroenke, K., Spitzer, R.L., Williams, J.B.W., 2002. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. *Psychosom. Med.* 64 (2), 258–266.
- Kroenke, K., Strine, T.W., Spitzer, R.L., Williams, J.B., Berry, J.T., Mokdad, A.H., 2009. The PHQ-8 as a measure of current depression in the general population. *J. Affect. Disord.* 114 (1–3), 163–173. <https://doi.org/10.1016/j.jad.2008.06.026>.
- Kroenke, K., Spitzer, R.L., Williams, J.B.W., Lowe, B., 2010. The Patient Health Questionnaire somatic, anxiety, and depressive symptom scales: a systematic review. *Gen. Hosp. Psychiatr.* 32, 345–359.
- Lemieux, A.C.C., Carnes, M., 2008. Symptom severity predicts degree of T cell activation in adult women following childhood maltreatment. *Brain Behav. Immun.* 22 (6), 994–1003. <https://doi.org/10.1016/j.bbi.2008.02.005>.
- Lindqvist, D., Dhabhar, F.S., Mellon, S.H., Yehuda, R., Grenon, S.M., Flory, J.D., Bierer, L.M., Abu-Amara, D., Coy, M., Makotkin, I., Reus, V.I., Saverio Bersani, F., Marmar, C.R., Wolkowitz, O.M., 2017. Increased pro-inflammatory milieu in combat related PTSD - a new cohort replication study. *Brain Behav. Immun.* 59, 260–264.
- Luna, J.M., Moon, Y.P., Liu, K.M., Spitalnik, S.L., Paik, M.C., Cheung, K., Sacco, R.L., Elkind, M.S.V., 2014. High-sensitivity C-reactive protein and interleukin-6—dominant inflammation and ischemic stroke risk. The northern manhattan study. *Stroke* 45, 979–987. <https://doi.org/10.1161/STROKEAHA.113.002289>.
- Mayo Clinic, 2020. Mayo Clinic CRP Tests and Procedures. Mayo Clinic.
- McHorney, C.A., Ware, J.J., Raczek, A.E., 1993. The MOS 36-item short-form health survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. *Med. Care* 13, 247–263. <https://doi.org/10.1097/00005650-199303000-00006>.
- Mendieta, D., del la Cruz Aguilera, D.L., Barrera-Villalpando, M.I., Becerril-Villanueva, L.E., Arreola, R., Hernández-Ferreira, E., Pérez-Tapia, S.M., Pérez-Sánchez, G., Garcés-Alvarez, M.E., Aguirre-Cruz, L., Velasco-Velázquez, M.A., Pavón, L., 2016. IL-8 and IL-6 primarily mediate the inflammatory response in fibromyalgia patients. *J. Neuroimmunol.* 290, 22–25. <https://doi.org/10.1016/j.jneuroim.2015.11.011>.

- Miller, G.E., Freedland, K.E., Carney, R.M., Stetler, C.A., Banks, W.A., 2003. Pathways linking depression, adiposity, and inflammatory markers in healthy young adults. *Brain Behav. Immun.* 17 (4), 276–285.
- Pasco, J.A., Nicholson, G.C., Williams, L.J., Jacka, F.N., Henry, M.J., Kotowicz, M.A., Schneider, H.G., Leonard, B.E., Berk, M., 2010. Association of high-sensitivity C-reactive protein with de novo major depression. *Br. J. Psychiatr.* 197, 372–377. <https://doi.org/10.1192/bjp.bp.109.076430>.
- Pearson, T.A., Menash, G.A., Alexander, R.W., Anderson, J.L., Cannon III, R.O., Criqui, M., Fadl, Y.Y., Fortmann, S.P., Hong, Y., Myers, G.L., Rifai, N., Smith Jr., S.C., Taubert, K., Tracy, R.P., Vinicor, F., 2003. Markers of inflammation and cardiovascular disease. Application to clinical and public health practice: a statement for healthcare professionals from the Centers for disease control and prevention and the American heart association. *Circulation* 107 (3), 499–511. <https://doi.org/10.1161/01.CIR.0000052939.59093.45>.
- Pedrotti Moreira, F., Wiener, C.D., Jansen, K., Portela, L.V., Lara, D.R., Diaas de Mattos Souza, L., da Silva, R.A., Oses, J.P., 2018. Childhood trauma and increased peripheral cytokines in young adults with major depressive disorder: population-based study. *J. Neuroimmunol.* 15 (319), 112–116. <https://doi.org/10.1016/j.jneuroim.2018.02.018>.
- Pfützner, A., Forst, T., 2006. High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus. *Review. Diab. Technol. Therap.* 8 (1), 28–36. Feb.
- Powers, A., Drew Dixon, H., Conneely, K., Gluck, R., Munoz, A., Rochat, C., Mendoza, H., Hartzell, G., Ressler, K.J., Bradley, B., Pace, T.W.W., Umpierrez, G.E., Schwartz, A.C., Michopoulos, V., Gillespie, C.F., 2019. The differential effects of PTSD, MDD, and dissociation on CRP in trauma-exposed women. *Compr. Psychiatr.* 93, 33–40. <https://doi.org/10.1016/j.comppsy.2019.06.007>.
- Quartana, P.J., Finan, P.H., Page, G.G., Smith, M.T., 2015. Effects of insomnia disorder and knee osteoarthritis on resting and pain-evoked inflammatory markers. *Brain Behav. Immun.* 228–237.
- Ridker, P.M., 2016. From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection. *Review. Circ. Res.* 8, 145–156. <https://doi.org/10.1161/CIRCRESAHA.115.306656>, 118(1).
- Rief, W., Mills, P.J., Ancoli-Israel, S., Ziegler, M.G., Pung, M.A., Dimsdale, J.E., 2010. Overnight changes of immune parameters and catecholamines are associated with mood and stress. *Psychosom. Med.* 72 (8), 755–762. <https://doi.org/10.1097/PSY.0b013e3181f367e2>. Epub2010 Sep 14.
- Scheller, J., Chalaris, A., Schmidt-Arras, D., Rose-John, S., 2011. The pro- and anti-inflammatory properties of the cytokine interleukin-6. *Biochim. Biophys. Acta* 1813, 878–888.
- Sheehan, D.V., Lecrubier, Y., Sheehan, K.H., Amorim, P., Janavs, J., Weiller, E., Hergueta, T., Baker, R., Dunbar, G.C., 1998. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *J. Clin. Psychiatr.* 22–33.
- Simon, N., McNamara, K., Chow, C.W., Maser, R.S., Gi, P., Pollack, M., Nirenberg, A.A., Fava, M., Wong, K.K., 2008. A detailed examination of cytokine abnormalities in major depressive disorder. *Eur. Neuropsychopharmacol.* 18, 230–233.
- Spitzer, R.L., Williams, J.B.W., Gibbon, M., First, M.B., 1990. User's Guide for the Structured Clinical Interview for DSM-III-R: SCID. American Psychiatric Association.
- Spitzer, R.L., Kroenke, K., Williams, J.B., Lowe, B., 2006. A brief measure for assessing generalized anxiety disorder: the GAD-7. *Arch. Intern. Med.* 166 (10), 1092–1097.
- Tan, G., Jensen, M.P., Thornby, J.I., Shanti, B.F., 2004. Validation of the brief pain inventory for chronic nonmalignant pain. *J. Pain* 5 (2), 133–137.
- Tanaka, T., Narazaki, M., Kishimoto, T., 2014. IL-6 in inflammation, immunity, and disease. *Cold Spring Harbor Perspect. Biol.* 6 (10) <https://doi.org/10.1101/cshperspect.a016295>.
- Tsalik, E.L., Jagers, L.B., Glickman, S.W., Langley, R.J., van Vilkinburgh, J.C., Park, L.P., Fowler, V.G., Cairns, C.B., Kingsmore, S.F., Woods, C.W., 2012. Discriminative value of inflammatory biomarkers for suspected sepsis. *J. Emerg. Med.* 43, 97–106.
- Uçeyler, N., Hauser, W., Sommer, C., 2011. Systematic review with meta-analysis: cytokines in fibromyalgia syndrome. *BMC Musculoskel. Disord.* 12, 245. <https://doi.org/10.1186/1471-2474-12-245>.
- van der Feltz-Cornelis, C.M., 2020. Diagnostic profiling in clinical translational research — a European perspective. *Eur. J. Psychiatr.* 34 (2 April–June), 57–62. <https://doi.org/10.1016/j.ejpsy.2019.11.003>.
- van der Feltz-Cornelis, C.M., Potters, E.C., van Dam, A., Koorndijk, R.P.M., Elfeddali, I., van Eck van der Sluijs, J.F., 2019. Adverse Childhood Experiences (ACE) in outpatients with anxiety and depressive disorders and their association with psychiatric and somatic comorbidity and revictimization. Cross-sectional observational study. *J. Affect. Disord.* 246, 458–464. <https://doi.org/10.1016/j.jad.2018.12.096>.
- Van Eck van der Sluijs, J.F., De Vroeghe, L., Van Manen, A.S., Rijnders, C., van der Feltz-Cornelis, C.M., 2017. Complexity assessed by the intermed in patients with somatic symptom disorder visiting a specialized outpatient mental health care setting: a cross-sectional study. *Psychosomatics* 58 (4), 427–436.
- Van Hemert, A.M., 2003. Physical Symptoms Questionnaire[in Dutch]. Leids Universitair Medisch Centrum, Leiden.
- Viljoen, M., Panzer, A., 2005. Non-termination of sickness behavior as precipitating factor for mental disorders. *Med. Hypotheses* 65 (2), 316–329.
- Vogelzangs, N., de Jonge, P., Smit, J.H., Bahn, S., Penninx, B.W., 2016. Cytokine production capacity in depression and anxiety. *Transl. Psychiatry* 6, e825.
- Volanakis, J.E., 2001. Human C-reactive protein: expression, structure, and function. *Mol. Immunol.* 38, 189–197.
- Ware, J.E., Sherbourne, C.D., 1992. The MOS 36-item short-form health survey (SF-36). *Med. Care* 30 (6), 473–483.
- Ware, J.E., Kosinski, M., Keller, S.D., 1994. SF-36 Physical and Mental Health Summary Scales - A User's Manual, second ed. New England Medical Center, The Health Institute, Boston, MA.
- Werner, K.B., McCutcheon, V.V., Challa, M., Agrawal, A., Lynskey, M., Conroy, E., Statham, D.J., Madden, P.A.F., Henders, A.K., Todorov, A.A., Heath, A.C., Degenhardt, L., Martin, N.G., Bucholz, K.K., Nelson, E.C., 2016. The association between childhood maltreatment, psychopathology, and adult sexual victimization in men and women: results from three independent samples. *Psychol. Med.* 46 (3), 563–573.
- Whicher, J.T., 1998. BCR/IRMM reference material for plasma proteins (CRM470). *Clin. Biochem.* 31, 459–465.
- World Health Organisation (WHO), 2016. International Classification of Diseases Tenth Edition (ICD-10). <https://www.who.int/classifications/icd/icdonlineversions/en/>. (Accessed 23 July 2020). Accessed online.
- Yudkin, J.S., Stehouwer, C.D., Emeis, J.J., Coppack, S.W., 1999. C-reactive protein in healthy subjects. Association with obesity, insulin resistance, and endothelial dysfunction. A potential role for cytokines originating from adipose tissue? *Arterioscler. Thromb. Vasc. Biol.* 19, 972–978.
- Zevin, S., Saunders, S., Gourlay, S.G., Jacob, P., Benowitz, N.L., 2001. Cardiovascular effects of carbon monoxide and cigarette smoking. *J. Am. Coll. Cardiol.* 38, 1633–1638.